Recipharm’s new CEO on ‘fast and furious’ changes, with eyes on GLP-1, biologics manufacturing

Just over three months in­to his new role as the CEO of Re­ci­pharm, Greg Be­har is al­ready mak­ing siz­able changes to the CD­MO’s en­gine.

“I’ve been study­ing the com­pa­ny deeply be­fore join­ing so that we could move fast and fu­ri­ous on the first of Jan­u­ary, and that’s what we’ve been do­ing,” Be­har told End­points News in an in­ter­view.

Ac­cord­ing to the CEO, the com­pa­ny’s re­cent moves re­flect its ef­forts to sim­pli­fy its port­fo­lio. A few weeks ago, Re­ci­pharm di­vest­ed sev­en man­u­fac­tur­ing sites that will be­come a new, yet-to-be-named CD­MO un­der Blue Wolf Cap­i­tal Part­ners. In No­vem­ber, Re­ci­pharm said it would spin out its in­haler busi­ness to be­come a sep­a­rate com­pa­ny al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.